首页> 外文期刊>EFSA Journal >Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and maintenance of normal cardiac function (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325), maintenance of normal blood glucose concentrations (ID 566), maintenance of normal blood pressure (ID 506, 516, 703, 1317, 1324), maintenance of normal blood HDL‐cholesterol concentrations (ID 506), maintenance of normal (fasting) blood concentrations of triglycerides (ID 506, 527, 538, 1317, 1324, 1325), maintenance of normal blood LDL‐cholesterol concentrations (ID 527, 538, 1317, 1325, 4689), protection of the skin from photo‐oxidative (UV‐induced) damage (ID 530), improved absorption of EPA and DHA (ID 522, 523), contribution to the normal function of the immune system by decreasing the levels of eicosanoids, arachidonic acid‐derived mediators and pro‐inflammatory cytokines (ID 520, 2914), and “immunomodulating agent” (4690) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
【24h】

Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and maintenance of normal cardiac function (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325), maintenance of normal blood glucose concentrations (ID 566), maintenance of normal blood pressure (ID 506, 516, 703, 1317, 1324), maintenance of normal blood HDL‐cholesterol concentrations (ID 506), maintenance of normal (fasting) blood concentrations of triglycerides (ID 506, 527, 538, 1317, 1324, 1325), maintenance of normal blood LDL‐cholesterol concentrations (ID 527, 538, 1317, 1325, 4689), protection of the skin from photo‐oxidative (UV‐induced) damage (ID 530), improved absorption of EPA and DHA (ID 522, 523), contribution to the normal function of the immune system by decreasing the levels of eicosanoids, arachidonic acid‐derived mediators and pro‐inflammatory cytokines (ID 520, 2914), and “immunomodulating agent” (4690) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

机译:关于证实二十碳五烯酸(EPA),二十二碳六烯酸(DHA),二十二碳五烯酸(DPA)和维持正常心脏功能的健康声明的科学意见(ID 504、506、516、527、538、703、1128、1317 ,1324,1325),维持正常血糖浓度(ID 566),维持正常血压(ID 506,516,703,1317,1324),维持正常血液HDL-胆固醇浓度(ID 506),维持正常(禁食)血液中甘油三酸酯的浓度(ID 506、527、538、1317、1324、1325),维持正常血液LDL-胆固醇的浓度(ID 527、538、1317、1325、4689),保护皮肤免受光照氧化(紫外线)损伤(ID 530),EPA和DHA的吸收得到改善(ID 522,523),通过降低类花生酸,花生四烯酸衍生的介体和促红细胞生成素的水平来促进免疫系统的正常功能炎性细胞因子(ID 520、2914)和“免疫调节剂”(4690)根据1924/2006号法规(EC)第13(1)条

获取原文
           

摘要

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition andAllergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 ofRegulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claimsin relation to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid(DPA) and maintenance of normal cardiac function, maintenance of normal blood glucoseconcentrations, maintenance of normal blood pressure, maintenance of normal blood HDL-cholesterolconcentrations, maintenance of normal (fasting) blood concentrations of triglycerides, maintenance ofnormal blood LDL-cholesterol concentrations, protection of the skin from photo-oxidative (UV-induced) damage, improved absorption of EPA and DHA, contribution to the normal function of theimmune system by decreasing the levels of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines, and “immunomodulating agent”. The scientific substantiation is based on theinformation provided by the Member States in the consolidated list of Article 13 health claims andreferences that EFSA has received from Member States or directly from stakeholders.
机译:根据欧洲委员会的要求,要求营养产品,营养和过敏问题小组根据1924/2006号法规(EC)第13条就健康声明清单提供科学意见。该意见涉及与二十碳五烯酸(EPA),二十二碳六烯酸(DHA),二十二碳五烯酸(DPA)有关的健康主张的科学依据,以及维持正常的心脏功能,维持正常的血糖浓度,维持正常的血压,维持正常的血压血液HDL-胆固醇浓度,维持正常(空腹)甘油三酸酯浓度,维持正常血液LDL-胆固醇浓度,保护皮肤免受光氧化(UV诱导)损伤,改善EPA和DHA的吸收,促进正常通过降低类花生酸,花生四烯酸衍生的介质和促炎细胞因子以及“免疫调节剂”的水平来发挥免疫系统的功能。科学依据是成员国在EFSA从成员国或直接从利益相关者那里获得的第13条健康声明和参考的综合清单中提供的信息。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号